ArticleJournal of clinical and experimental hematopathology : JCEH2020
The clinical impact of absolute lymphocyte count in peripheral blood among patients with methotrexate - associated lymphoproliferative disorders.
Article in Journal of clinical and experimental hematopathology : JCEH, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- Methotrexate-Associated Systemic Lymphadenopathy Exhibiting a Marked Elevation of the Serum IgG4 Concentrations.Internal medicine (Tokyo, Japan) · 2026Article
- Retrospective Study of 68 Patients with Rheumatoid Arthritis-associated Lymphoproliferative Diseases Treated with Methotrexate.Internal medicine (Tokyo, Japan) · 2026Observational
- Diffuse thyroid enlargement and its regression in methotrexate-associated lymphoproliferative disorder: an ultrasonographic observation.Endocrinology, diabetes & metabolism case reports · 2025Article
- Spontaneous Regression of Plasmablastic Lymphoma Associated With Methotrexate After Withdrawal.Journal of hematology · 2024Article
- Spontaneous regression of multiple solitary plasmacytoma harboring Epstein-Barr virus: a case report and literature review.International journal of hematology · 2024Review
- A case of classic Hodgkin lymphoma arising after remission of methotrexate-associated follicular lymphoma.Journal of clinical and experimental hematopathology : JCEH · 2023Article
- Lymphoproliferative disorder risk after methotrexate treatment for rheumatoid arthritis.Cancer science · 2023Article
- FDG-PET/CT imaging parameters for predicting spontaneous regression of methotrexate-associated lymphoproliferative disorder in patients with rheumatoid arthritis.Scientific reports · 2022Article
- Angioimmunoblastic T-cell Lymphoma Presenting as a Methotrexate-associated Lymphoproliferative Disorder with Extreme Peripheral Blood Plasmacytosis.Internal medicine (Tokyo, Japan) · 2022Article
- PD-L1 expression is associated with the spontaneous regression of patients with methotrexate-associated lymphoproliferative disorders.Cancer medicine · 2022Article
- Disappearance of bulky diffuse large B-cell lymphoma after methotrexate/infliximab withdrawal.International journal of hematology · 2022Article
- Clinicopathological evaluation of methotrexate-associated lymphoproliferative disorders with special focus on Epstein-Barr virus-positive mucocutaneous lesions.Journal of clinical and experimental hematopathology : JCEH · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Regressive lymphoproliferative disorders (R-LPD) after methotrexate (MTX) withdrawal are one of the specific features of methotrexate - associated lymphoproliferative disorders (MTX-LPD). Although the impact of the absolute lymphocyte count (ALC) on the pathogenesis of R-LPD has been recently emphasized, understanding relapse/regrowth events (RRE) and differences among LPD subtypes is necessary. In this study, we confirmed ALC recovery in the regressive group (R-G; R-LPD without RRE) and relapse/regrowth group (R/R-G; R-LPD with RRE). The increase in ALC lasted at least 2 years in R-G, whereas it decreased within 3 years in R/R-G, supporting the better overall survival (OS) in R-G, as previously reported. In addition, our study suggested that an ALC of 1000/µL at the time of development of LPD is a significant predictor for treatment-free survival (TFS). Furthermore, an ALC of 1000/µL at 6 months after MTX withdrawal was found to be a significant indicator of TFS and OS for R-G and R/R-G. The ALC decreased gradually before LPD development in R/R-G, whereas it decreased 6 months before LPD development in R-G, confirming the important role of ALC in the pathogenesis of MTX-LPD such as regressive events and RRE. In addition to ALC, other predictive factors, such as serum C-reactive protein and soluble interleukin-2 receptors, may be helpful in the management of MTX-LPD, including the decision making for an additional chemotherapy for regressive LPD after MTX withdrawal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.